CHAPTER 7: Galectin-3 Involvement in Fibrotic Diseases

Xiaosong Jiang, Natalie J. Torok, Joseph J. Barchi

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

A variety of signaling pathways contribute to initiating the pathologies associated with fibrotic disease. Galectins are a group of beta-galactoside-binding proteins that are involved in a host of cellular processes, some of which contribute to fibrosis in different organs. Accumulating evidence indicates that of these, Galectin-3 (Gal-3) is a pathogenic mediator in fibrotic diseases in many different organs. The atypical Gal-3 contains a single carbohydrate recognition domain (CRD) attached to an N-terminal peptide sequence that putatively nucleates the formation of oligomers that can form lattice networks when bound to multiple cellular glycans. Pharmacological or genetic knockdown of Gal-3 has been shown to inhibit fibrosis in several organs, and thus has emerged as a valid therapeutic target. This chapter will review the structure and function of Gal-3 and attempt to validate the important role it plays in fibrosis. In addition, the current state of pharmaceutical discovery of Gal-3 inhibitors will be outlined and discussed in the context of fibrotic disease of the heart, liver, lungs and kidneys. A discussion of the challenges facing future Gal-3 inhibitor development for targeting fibrosis will also be included.

Original languageEnglish (US)
Title of host publicationAnti-fibrotic Drug Discovery
EditorsJehrod Brenneman, Malliga R. Iyer
PublisherRoyal Society of Chemistry
Pages185-210
Number of pages26
Edition73
DOIs
StatePublished - Jan 1 2020

Publication series

NameRSC Drug Discovery Series
Number73
Volume2020-January
ISSN (Print)2041-3203
ISSN (Electronic)2041-3211

ASJC Scopus subject areas

  • Drug Discovery

Fingerprint Dive into the research topics of 'CHAPTER 7: Galectin-3 Involvement in Fibrotic Diseases'. Together they form a unique fingerprint.

  • Cite this

    Jiang, X., Torok, N. J., & Barchi, J. J. (2020). CHAPTER 7: Galectin-3 Involvement in Fibrotic Diseases. In J. Brenneman, & M. R. Iyer (Eds.), Anti-fibrotic Drug Discovery (73 ed., pp. 185-210). (RSC Drug Discovery Series; Vol. 2020-January, No. 73). Royal Society of Chemistry. https://doi.org/10.1039/9781788015783-00185